TruNiagen
TruNiagen

Innovation

Longeveron completes longevity clinical trial

Longeveron announces successful completion of phase 2b clinical study of Lomecel-B infusion to treat aging frailty. Longeveron Inc, a clinical...

Study suggests new treatment for diabetes

Melbourne researchers awaken key progenitor cells by DNA demethylation in diabetes study. Type 2 diabetes is a serious condition that greatly impacts the health, wellbeing...

SuperAger brains work all the tangles

New research demonstrates that SuperAger brains can resist the protein tangles that lead to Alzheimer's. Northwestern Medicine scientists have showed that SuperAgers' brains have resistance...

Latest news

Elastrin limbers up for success with Kizoo funding boost

Kizoo provides seed funding for Elastrin Therapeutics to develop ground-breaking new technology capable of reversing tissue and organ calcification. It was announced today that Elastrin,...

Study suggests new treatment for diabetes

Melbourne researchers awaken key progenitor cells by DNA demethylation in diabetes study. Type 2 diabetes is a serious condition that greatly impacts the health, wellbeing...

$125m secured for xenotransplantation human trials

Series C proceeds will advance two lead xenotransplantation programmes in kidney failure and type 1 diabetes into first-in-human studies. eGenesis, a gene-editing and genome-engineering company...

SuperAger brains work all the tangles

New research demonstrates that SuperAger brains can resist the protein tangles that lead to Alzheimer's. Northwestern Medicine scientists have showed that SuperAgers' brains have resistance...

Gene-editing tool can programme cuts over time

New process uses special molecules called 'proGuides' to improve CRISPR gene editing. Researchers from the University of Illinois Chicago have discovered a new gene-editing technique...

AI first: novel drug target and novel molecule discovered

One step closer to senescence moonshot: Insilico claims industry first by nominating preclinical candidate for IPF, with both novel drug target and novel molecule...

International Day of Women and Girls in Science

As we celebrate International Day of Women and Girls in Science, here are just a few of the names to be found in our...

Repair Bio’s novel platform – and exclusive from CEO

Proprietary Cholesterol Degrading Platform set to be an atherosclerosis game-changer. Repair Biotechnologies is a preclinical biotechnology company based in Syracuse, New York. Focused on developing...

Turn Bio expands mRNA platform with artificial niche tech

Turn Biotechnologies expands the potential of its mRNA platform by licensing unique artificial niche technology. Turn Biotechnologies announced today that it has acquired the global rights...
ChromaDex Tru Niagen
Longevity.Technology welcome banner

Obesity may exacerbate the effects of Alzheimer’s

New research finds being overweight is an additional burden on brain health – and it may exacerbate Alzheimer’s disease. Researchers from the University of Sheffield...

2021 hits the longevity ground running

Highlights from longevity research, trials and funding in January 2021 Hundreds of companies are working to develop treatments to slow down aging and increase healthy...

Cellino closes $16m seed financing

Massachusetts-based biotech announces closing of $16m seed round led by The Engine and Khosla Ventures. Cellino has raised $16 million in seed venture capital in...

AI fast-tracks human longevity extension

Top longevity leaders frame how next-gen AI can extend lifespan. Deep Longevity, which specialises in the development and the application of next-generation AI for aging...

Most popular

Longevity companies to watch in 2021

As the world enters the new year with a vaccine and an increased focus on geroprotection, there’s much to look forward to. Research from the...

AI first: novel drug target and novel molecule discovered

One step closer to senescence moonshot: Insilico claims industry first by nominating preclinical candidate for IPF, with both novel drug target and novel molecule...

Repair Bio’s novel platform – and exclusive from CEO

Proprietary Cholesterol Degrading Platform set to be an atherosclerosis game-changer. Repair Biotechnologies is a preclinical biotechnology company based in Syracuse, New York. Focused on developing...

Elastrin limbers up for success with Kizoo funding boost

Kizoo provides seed funding for Elastrin Therapeutics to develop ground-breaking new technology capable of reversing tissue and organ calcification. It was announced today that Elastrin,...
Apollo Neuro

You might also like

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...

OneSkin: turning back time for your skin

Skin rejuvenating cream goes more than skin deep with senotherapeutic treatment. Last year we reported on the launch of OneSkin, a topical senotherapeutic skin treatment...

New aging clock is a key longevity tool

A new aging clock that's close to the theoretical limit of accuracy boasts unprecedented precision and offers new insights into how the aging process...

Longeveron completes longevity clinical trial

Longeveron announces successful completion of phase 2b clinical study of Lomecel-B infusion to treat aging frailty. Longeveron Inc, a clinical stage biotechnology company developing cellular...

Plastic surgery in-a-box: a cryo biotech innovation

Future-facing Uvence is innovating for the future of your face. The biotech market is growing, as coverage on Longevity.Technology evidences. The ripples of biotech innovation...
TruNigen pf